Verano Holdings (VRNO) Total Current Liabilities (2021 - 2026)
Verano Holdings (VRNO) posted quarterly Total Current Liabilities of $118.9 million for Q1 2026, down 29.07% year-over-year from $167.6 million in Q1 2025, and down 15.22% quarter-over-quarter from $140.3 million in Q4 2025.
Verano Holdings (VRNO) Total Current Liabilities (2021 - 2026) Analysis & Trends
Verano Holdings (VRNO) has reported Total Current Liabilities for 6 consecutive years, with $118.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities fell 29.07% year-over-year to $118.9 million; the TTM figure through Mar 2026 stood at $118.9 million (down 29.07% YoY), while the FY2025 annual figure was $140.3 million, down 30.94% from the prior year.
- Total Current Liabilities declined to $118.9 million in Q1 2026 per VRNO's latest filing, from $140.3 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $586.8 million in Q2 2022 and bottomed at $118.9 million in Q1 2026.
- Historically, Total Current Liabilities has averaged $310.4 million across 5 years, with a median of $356.4 million in 2023.
- Annual changes were most pronounced in 2024 — Total Current Liabilities grew 23.58% — and 2025, when it plunged 67.06%.
- Verano Holdings' Total Current Liabilities stood at $386.6 million in 2022, then rose by 6.61% to $412.2 million in 2023, then plunged by 50.72% to $203.1 million in 2024, then slumped by 30.94% to $140.3 million in 2025, then decreased by 15.22% to $118.9 million in 2026.
- Business Quant data shows VRNO's Total Current Liabilities at $118.9 million in Q1 2026, $140.3 million in Q4 2025, and $143.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | -8.38 Bn |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn | 15.65 Bn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn | 2.06 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 17.34 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | 6.35 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 874.50 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 1.85 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | 1.79 Bn |
| 10 | Verano Holdings | 438.82 Mn | 353.62 Mn | 99.70 Mn | 109.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 109.37 Mn |
| Mar 31, 2026 | 118.91 Mn |
| Dec 31, 2025 | 140.26 Mn |
| Sep 30, 2025 | 143.41 Mn |
| Jun 30, 2025 | 147.83 Mn |
| Mar 31, 2025 | 167.64 Mn |
| Dec 31, 2024 | 203.11 Mn |
| Sep 30, 2024 | 435.38 Mn |
| Jun 30, 2024 | 360.59 Mn |
| Mar 31, 2024 | 414.98 Mn |
| Dec 31, 2023 | 412.19 Mn |
| Sep 30, 2023 | 352.30 Mn |
| Jun 30, 2023 | 348.32 Mn |
| Mar 31, 2023 | 363.39 Mn |
| Dec 31, 2022 | 386.65 Mn |
| Sep 30, 2022 | 384.20 Mn |
| Jun 30, 2022 | 586.78 Mn |
| Dec 31, 2021 | 470.52 Mn |